Connor, Clark & Lunn Investment Management (CC&L)’s Fulcrum Therapeutics FULC Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.73M	Buy	745,317 +8,633	+1%	+$52.5K	0.01%	913
2026 Q1	$5.65M	Buy	736,684 +154,307	+26%	+$1.43M	0.01%	646
2025 Q4	$6.59M	Buy	582,377 +198,239	+52%	+$2.02M	0.02%	572
2025 Q3	$3.53M	Buy	384,138 +41,591	+12%	+$301K	0.01%	681
2025 Q2	$2.36M	Buy	342,547 +124,798	+57%	+$668K	0.01%	815
2025 Q1	$627K	Sell	217,749 -149,845	-41%	-$550K	﹤0.01%	1086
2024 Q4	$1.73M	Buy	367,594 +234,810	+177%	+$866K	0.01%	767
2024 Q3	$474K	Buy	+132,784	New	+$985K	﹤0.01%	1111

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s FULC Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Fulcrum Therapeutics (FULC) stake by 1.2% in Q2 2026, buying an estimated $52.5K and bringing the position to 745,317 shares worth $2.73M. The position accounts for 0.01% of the portfolio, ranked #913.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in FULC in Q3 2024 and has held it in 8 quarters since. The position peaked at $6.59M in Q4 2025. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 745,317 shares of Fulcrum Therapeutics worth $2.73M as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) bought 8,633 Fulcrum Therapeutics shares in Q2 2026, an estimated $52.5K.
Fulcrum Therapeutics made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #913 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Fulcrum Therapeutics in Q3 2024 and has held it in 8 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Fulcrum Therapeutics position peaked at $6.59M in Q4 2025.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.